Shattuck Labs Inc. Common Stock (STTK)

FairStock Score: 52/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look at Shattuck Labs as an early-stage drug developer, not a proven business. It is developing SL-325 and SL-425 for inflammatory and immune-mediated diseases, and the FairStock Peter Lynch category is none because it lost money in each of the last four years. The filed figures show why: fiscal 2023, year ended 2023-12-31, revenue $1.7M and net loss $87.3M; fiscal 2024, year ended 2024-12-31, revenue $5.7M and net loss $75.4M; fiscal 2025, year ended 2025-12-31, revenue $1.0M and net loss $48.8M. In fiscal Q3 2025, quarter ended 2025-09-30, revenue was $1.0M and net loss was $10.1M. In fiscal Q1 2026, quarter ended 2026-03-31, net loss was $14.8M, and in fiscal Q2 2026, quarter ended 2026-06-30, net loss was $15.2M. Those are not earnings that support a conventional valuation. The balance sheet shows low debt, with debt-to-equity of 0.01, and FairStock calculates an Altman Z-Score of 32.73. But that does not create a moat. FairStock calculates a Piotroski F-Score of 2/9, trailing free cash flow of -$41.2M, and FCF yield of -7.5%. At the 2026-10-13 close of $5.49, market cap is $551.0M; FairStock calculates negative P/E of -12.48, P/B of 2.61, ROE of -39.21%, and ROCE of -24.43%. Paying $551.0M for a business with $1.0M of fiscal 2025 revenue and continuing losses is a bet on future pipeline success, not present value. Growth depends on clinical progress, but the financial record shows persistent losses and cash consumption. Without durable revenue or profits, there is no margin of safety in the Graham sense. I see a speculative biotech with a 52/100 FairStock score, not a compounding value investment.

In plain English: Shattuck Labs is a small early-stage drug company trying to develop antibody medicines for inflammatory and immune diseases. It has very little revenue and has been losing money, with 40 employees and no consistent profits. At the 2026-10-13 close of $5.49, the company is valued at about $551 million, which looks expensive compared with its current business results.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer